Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
Stopped Study is unlikely to be feasible given the evolving ovarian cancer landscape and alternative studies have the potential to meet future clinical demand.
Conditions
- Platinum Sensitive Relapsed Ovarian Cancer
Interventions
- DRUG: OLAPARIB
- DRUG: PLACEBO
Sponsor
AstraZeneca
Collaborators